Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myriam Labopin

Showing results (141-150 of 443) with videos related to

Pageof 45
Sort By:
Oncotarget|February 10, 2018
Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remissionFrancesco Saraceni, Myriam Labopin, Rose-Marie Hamladji, et al.
British Journal of Haematology|August 14, 2025
Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow TransplantationAvichai Shimoni, Christophe Peczynski, Myriam Labopin, et al.
Oncotarget|December 20, 2018
Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TCAmandine Le Bourgeois, Myriam Labopin, Mathieu Leclerc, et al.
American Journal of Hematology|May 26, 2020
Impact of detectable measurable residual disease on umbilical cord blood transplantationFrédéric Baron, Myriam Labopin, Annalisa Ruggeri, et al.
Blood|July 5, 2019
Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantationGiorgia Battipaglia, Myriam Labopin, Nicolaus Kröger, et al.
Blood|July 9, 2008
A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantationFabio Ciceri, Myriam Labopin, Franco Aversa, et al.
Journal of Hematology & Oncology|September 19, 2016
Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT studyAnnalisa Ruggeri, Giorgia Battipaglia, Myriam Labopin, et al.
Journal of Hematology & Oncology|April 18, 2018
Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMTNicole Santoro, Myriam Labopin, Federica Giannotti, et al.
Cancer|May 17, 2024
Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working PartyAbdul-Hamid Bazarbachi, Myriam Labopin, Anna Maria Raiola, et al.
Transplantation|March 20, 2013
Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignanciesVanderson Rocha, Myriam Labopin, Annalisa Ruggeri, et al.
Pageof 45

Showing results (141-150 of 443) with videos related to

Sort By:
Pageof 45
Oncotarget|February 10, 2018
Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remissionFrancesco Saraceni, Myriam Labopin, Rose-Marie Hamladji, et al.
British Journal of Haematology|August 14, 2025
Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow TransplantationAvichai Shimoni, Christophe Peczynski, Myriam Labopin, et al.
Oncotarget|December 20, 2018
Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TCAmandine Le Bourgeois, Myriam Labopin, Mathieu Leclerc, et al.
American Journal of Hematology|May 26, 2020
Impact of detectable measurable residual disease on umbilical cord blood transplantationFrédéric Baron, Myriam Labopin, Annalisa Ruggeri, et al.
Blood|July 5, 2019
Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantationGiorgia Battipaglia, Myriam Labopin, Nicolaus Kröger, et al.
Blood|July 9, 2008
A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantationFabio Ciceri, Myriam Labopin, Franco Aversa, et al.
Journal of Hematology & Oncology|September 19, 2016
Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT studyAnnalisa Ruggeri, Giorgia Battipaglia, Myriam Labopin, et al.
Journal of Hematology & Oncology|April 18, 2018
Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMTNicole Santoro, Myriam Labopin, Federica Giannotti, et al.
Cancer|May 17, 2024
Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working PartyAbdul-Hamid Bazarbachi, Myriam Labopin, Anna Maria Raiola, et al.
Transplantation|March 20, 2013
Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignanciesVanderson Rocha, Myriam Labopin, Annalisa Ruggeri, et al.
Pageof 45